Outlook Therapeutics
A late clinical-stage biopharmaceutical company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $13.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 408 % | 228 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (784 %) | (73 %) | 29 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing innovative ophthalmic treatments. The company is currently advancing ONS-5010, an investigational ophthalmic formulation of bevacizumab, through clinical trials for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases such as diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). ONS-5010 is designed to be administered as an intravitreal injection, directly into the eye, to inhibit vascular endothelial growth factor (VEGF) and associated angiogenic activity, which are key factors in these retinal conditions. If approved, ONS-5010 will be the first and only FDA-approved ophthalmic formulation of bevacizumab for these indications.
The company operates in the biopharmaceutical market, primarily serving patients with retinal diseases and collaborating with healthcare providers and research institutions. Outlook Therapeutics' business model revolves around the development, clinical testing, and eventual commercialization of its proprietary ophthalmic formulations. Revenue generation is expected to come from the sale of FDA-approved treatments and potential partnerships or licensing agreements with other pharmaceutical companies.
Keywords: ophthalmic treatments, wet AMD, retinal diseases, bevacizumab, intravitreal injection, VEGF inhibition, clinical trials, biopharmaceutical, FDA approval, innovative therapies.